Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Myeloproliferative Disorders × Busulfan × Clear all

Phase

Status

Completed 38 Terminated 9 Recruiting 4 Withdrawn 2 Active not recruiting 2 Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 5 Hematologic Neoplasms 2 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Older Patients 1 Neuroblastoma 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Lymphoma 1 Leukemia 1 Graft vs Host Disease 1

Interventions

peginterferon alfa-2b 1 Specimen Handling 1 Resistance Training 1 Quality of Life 1 Phlebotomy 1 Observation 1 Levofloxacin 1 Exercise 1 Electrocardiography 1 Echocardiography 1 Clinical Laboratory Techniques 1 Busulfan 1 Bone Marrow Examination 1 Biopsy 1 Azacitidine 1 Aspirin 1 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04451200 2020-11-17

BUSEQ

Institut Paoli-Calmettes

Phase 2 Not yet recruiting

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡